Business
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned. As part of the commissioning process
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"LOS ANGELES, Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned. As part of the commissioning process, the U.S. Food and Drug Administration (the "FDA") has been notified that production has commenced, and full production runs have been completed with no issues or concerns.","length":756,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bvnlEtALuiGK.3Dxno4EVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""The full commissioning of our state-of-the-art manufacturing facility in Los Angeles represents a key milestone for Armata, ensuring that we are operationally ready to initiate pivotal studies of our phage-based therapeutics," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "Importantly, this facility reflects our commitment to onshore manufacturing, from procurement of active pharmaceutical ingredients through fill and finish activities, to ensure that we can achieve the quality, quantity, and consistency of high-purity phage that our clinical programs require, while aligning with the federal government's efforts to further secure the essential medicine supply chain through domestic manufacturing. With this production facility now online, I believe we have taken another meaningful step forward in our...